Fostamatinib
Back to searchMolecule Structure
Scientific Name
Fostamatinib
Description of the Drug
Fostamatinib is a spleen tyrosine kinase inhibitor used to treat chronic immune thrombocytopenia after attempting one other treatment.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB12010
http://www.drugbank.ca/drugs/DB12010
Brand Name(s)
Not Available
Company Owner(s)
Rigel Pharmaceuticals Inc
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| Tyrosine-protein kinase SYK | SINGLE PROTEIN | INHIBITOR | CHEMBL2599 |
Clinical Trial(s)
Unichem Links
| SureChEMBL | SCHEMBL1201371 | ||
| Human Metabolome Database | HMDB0252469 | ||
| DrugBank | DB12010 | ||
| PubChem: Thomson Pharma | 16775273 | ||
| PubChem | 11671467 | ||
| Nikkaji | J2.688.712G | ||
| PDBe | 2RC | ||
| BindingDB | 50431381 | ||
| DrugCentral | 5280 | ||
| ChemicalBook | CB52499223 | ||
| Guide to Pharmacology | 7796 | ||
| rxnorm | FOSTAMATINIB | FOSTAMATINIB DISODIUM | TAVALISSE |
| PubChem: Drugs of the Future | 125299332 | ||
| ZINC | ZINC000043131420 |
